|1.||Mantzoros, Christos S: 10 articles (02/2013 - 05/2003)|
|2.||Chan, Jean L: 8 articles (02/2009 - 05/2003)|
|3.||Gorden, Phillip: 7 articles (04/2008 - 02/2002)|
|4.||DePaoli, Alex M: 6 articles (05/2005 - 02/2002)|
|5.||Depaoli, Alex M: 5 articles (09/2007 - 07/2002)|
|6.||Oral, Elif Arioglu: 4 articles (04/2005 - 02/2002)|
|7.||Lee, Jennifer H: 3 articles (02/2009 - 06/2004)|
|8.||Wong, Ma-Li: 3 articles (12/2008 - 05/2005)|
|9.||Licinio, Julio: 3 articles (12/2008 - 05/2005)|
|10.||Cochran, Elaine K: 3 articles (04/2008 - 04/2005)|
07/01/2006 - "Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy."
04/01/2004 - "Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome."
04/01/2004 - "This is the first report of a partial, but significant, effect of r-metHuLeptin administration in patients with extreme insulin resistance with a presumed insulin receptor mutation and low serum triglyceride levels."
12/01/2008 - "Insulin resistance was determined by euglycemic hyperinsulinemic clamps and by oral glucose tolerance tests (OGTTs), whereas patients were on r-metHuLeptin and after treatment was interrupted for 2-4 wk in the 4th, 5th, and 6th years of treatment. "
12/01/2008 - "We conclude that, in leptin-deficient adults, the interruption of r-metHuLeptin decreases insulin resistance in the context of rapid weight gain. "
04/01/2008 - "In the context of previously published work, our findings suggest that the response to r-MetHuLeptin is independent of the aetiology in lipodystrophy."
04/01/2008 - "A 36-year-old female with PL associated with a heterozygous PPARG mutation complicated by poorly controlled diabetes and severe, refractory hypertriglyceridaemia was enrolled in a National Institutes of Health (NIH) protocol to evaluate the role of r-metHuLeptin in lipodystrophy. "
07/01/2002 - "Seven female patients (aged 15-42 yr, all diabetic) with lipodystrophy and serum leptin levels less than 4 mg/liter were treated with recombinant methionyl-human leptin (recombinant leptin) in physiological doses in an open-labeled study. "
09/01/2004 - "To examine leptin's role in human appetite regulation, we studied recombinant methionyl human leptin's effects on satiation and satiety in a model of leptin insufficiency, lipodystrophy. "
02/21/2002 - "Nine female patients (age range, 15 to 42 years; eight with diabetes mellitus) who had lipodystrophy and serum leptin levels of less than 4 ng per milliliter (0.32 nmol per milliliter) received recombinant methionyl human leptin (recombinant leptin). "
|3.||Weight Loss (Weight Reduction)
09/01/2007 - "To compliment the acute study, we retrospectively analyzed available BP results from a previously performed 85-day, placebo-controlled, randomized, double-blind, parallel weight-loss study using r-metHuLeptin in 284 obese adults. "
12/01/2008 - "The female patient with type 2 diabetes became euglycemic after treatment with r-metHuLeptin and subsequent weight loss. "
09/01/2007 - "In the retrospective analysis of the weight loss study data, 10 mg every day before noon (QAM), 10 mg every day after noon (QPM), or 10 mg twice a day (BID) SC of r-metHuLeptin was found to not alter the degree of weight loss (-3.2 +/- 3.7 versus -2.9 +/- 3.2 Kg, P = .54), change in systolic (-1.6 + 12.9 versus -2.0 +/- 13.9 mmHg, P = .85) and diastolic BP (-0.2 +/- 8.7 versus -1.5 +/- 8.6, P = .30), as well as heart rate (-1.4 +/- 10.7 versus -1.4 +/- 10.4 beats/min, P = .98) compared to placebo. "
10/01/2012 - "However, if r-metHuLeptin treatment has been shown to be dramatically efficient in leptin-deficient states, its very limited effect in inducing weight loss in common obese patients revealed that, in patients with adequate leptin secretion, mechanisms of leptin resistance and leptin tolerance prevent r-metHuLeptin from inducing any additional effects. "
01/01/2008 - "Within each group, the subjects lost approximately 3-4 kg of bodyweight after 3 days of fasting (all p < 0.0001), but the amount and time course of weight loss did not differ according to the dose of r-metHuLeptin administered or the circulating leptin concentrations achieved. "
|4.||Metabolic Diseases (Metabolic Disease)
08/01/2007 - "The objective of this study was to test safety and efficacy of recombinant-methionyl-human leptin replacement in children with Berardinelli-Seip syndrome before development of severe metabolic disease As part of an open trial, recombinant-methionyl-human leptin was given daily for 4 months to children who did not have diabetes and had Berardinelli-Seip congenital lipoatrophy and metabolic complications at a dosage that was meant to achieve physiologic levels. "
|2.||recombinant methionyl human leptin
|4.||Berardinelli-Seip congenital lipodystrophy type 2
|5.||Lamin Type A (Lamin A)
|8.||P-30 composite resin (P 30)
|9.||Insulin-Like Growth Factor I (IGF-1)
|1.||Highly Active Antiretroviral Therapy (HAART)